Treatment options for H5N1: lessons learned from the H1N1 pandemic - PubMed

Affiliations

• PMID: 20861597
• DOI: 10.3810/pgm.2010.09.2210

Review

Treatment options for H5N1: lessons learned from the H1N1 pandemic

Phillip Andrew Reece. Postgrad Med. 2010 Sep.

Abstract

Human infections with avian influenza A (H5N1) are relatively rare but are associated with high mortality. As of July 5, 2010 there had been 500 cases and 296 fatalities. The influenza virus readily undergoes mutation and reassortment, and there are concerns that an H5N1 variant could be responsible for a future pandemic. The influenza neuraminidase inhibitors zanamivir and oseltamivir are approved for the treatment and prophylaxis of influenza. Oseltamivir is being used to treat H5N1 infections and the case has been made for a role for zanamivir; however, there are no case reports for the latter. Zanamivir is a potent inhibitor of H5N1, attains high lung concentrations immediately on administration, distributes into plasma at antiviral concentrations, has a low propensity for generating resistant virus, and retains activity against H275Y oseltamivir-resistant virus. There have been several reports of oseltamivir-resistant H5N1 arising during treatment with oseltamivir, and zanamivir retains effectiveness (in vitro or in vivo) against these isolates. Compassionate use of intravenous zanamivir for the treatment of seriously ill patients, including those with H275Y H1N1 infections, has also shown promising results. It is concluded that there is a role for zanamivir in treating H5N1 infections either as the approved, inhaled formulation in patients capable of using the Diskhaler, or as the intravenous formulation if compassionate use is warranted. The relatively small number of patients with these infections remains an obstacle to completion of clinical trials. Evidence is therefore likely to be based on carefully documented case reports, ideally in patients treated early in the course of the infection.

Similar articles

• Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.

  Tamura D, DeBiasi RL, Okomo-Adhiambo M, Mishin VP, Campbell AP, Loechelt B, Wiedermann BL, Fry AM, Gubareva LV. Tamura D, et al. J Infect Dis. 2015 Oct 15;212(8):1209-13. doi: 10.1093/infdis/jiv245. Epub 2015 May 5. J Infect Dis. 2015. PMID: 25943200

• Neuraminidase inhibitor resistance in influenza viruses.

  Reece PA. Reece PA. J Med Virol. 2007 Oct;79(10):1577-86. doi: 10.1002/jmv.20951. J Med Virol. 2007. PMID: 17705169 Review.

• Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.

  Ikematsu H, Kawai N. Ikematsu H, et al. Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. doi: 10.1586/eri.11.112. Expert Rev Anti Infect Ther. 2011. PMID: 21973296 Review.

• [Current anti-influenza virus chemotherapy].

  Yoshioka D, Tokimatsu I, Ishii H, Kadota J. Yoshioka D, et al. Nihon Rinsho. 2010 Sep;68(9):1679-84. Nihon Rinsho. 2010. PMID: 20845747 Review. Japanese.

• Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection.

  Esposito S, Molteni CG, Colombo C, Daleno C, Daccò V, Lackenby A, Principi N. Esposito S, et al. J Clin Virol. 2010 May;48(1):62-5. doi: 10.1016/j.jcv.2010.02.019. Epub 2010 Mar 23. J Clin Virol. 2010. PMID: 20335065

Cited by

• Virus-induced acute respiratory distress syndrome: epidemiology, management and outcome.

  Luyt CÉ, Combes A, Trouillet JL, Nieszkowska A, Chastre J. Luyt CÉ, et al. Presse Med. 2011 Dec;40(12 Pt 2):e561-8. doi: 10.1016/j.lpm.2011.05.027. Epub 2011 Nov 16. Presse Med. 2011. PMID: 22094172 Free PMC article. Review.

• Comprehensive computational analysis reveals H5N1 influenza virus-encoded miRNAs and host-specific targets associated with antiviral immune responses and protein binding.

  Noor F, Saleem MH, Javed MR, Chen JT, Ashfaq UA, Okla MK, Abdel-Maksoud MA, Alwasel YA, Al-Qahtani WH, Alshaya H, Yasin G, Aslam S. Noor F, et al. PLoS One. 2022 May 9;17(5):e0263901. doi: 10.1371/journal.pone.0263901. eCollection 2022. PLoS One. 2022. PMID: 35533150 Free PMC article.

• Broad cross-reactive epitopes of the H5N1 influenza virus identified by murine antibodies against the A/Vietnam/1194/2004 hemagglutinin.

  Kobayashi-Ishihara M, Takahashi H, Ohnishi K, Nishimura K, Terahara K, Ato M, Itamura S, Kageyama T, Tsunetsugu-Yokota Y. Kobayashi-Ishihara M, et al. PLoS One. 2014 Jun 19;9(6):e99201. doi: 10.1371/journal.pone.0099201. eCollection 2014. PLoS One. 2014. PMID: 24945805 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program